Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates

A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00765687

Acronym

BLEST

Enrollment

432

Registered

2008-10-03

Start date

2008-08-31

Completion date

2012-05-31

Last updated

2013-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases, Non-small Cell Lung Cancer

Brief summary

A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.

Interventions

DRUGbisphosphates

any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Age \>18, either sex 2. Histologically confirmed non-small cell cancer 3. One bone metastasis at least confirmed by image(X ray,CT or others) 4. Without receiving zoledronic acid 5. Life expectancy \> 6 M 6. ECOG \<= 2 7. Signed ICF

Exclusion criteria

1. Women who are pregnant or in lactation 2. Patients with hyperostosis 3. with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled 4. Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy 5. Severe co-morbidity of any type that may interfere with assessment of the patient for the study -

Design outcomes

Primary

Measure	Time frame
Skeleton-related event	24 months

Secondary

Measure	Time frame
overall survival	24 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026